Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
Stock Information for Pluristem Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.